| Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy K Arvanitakis, I Mitroulis, G Germanidis Cancers 13 (12), 2899, 2021 | 68 | 2021 |
| Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy K Arvanitakis, T Koletsa, I Mitroulis, G Germanidis Cancers 14 (1), 226, 2022 | 66 | 2022 |
| Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries JC Glasbey, TEF Abbott, A Ademuyiwa, A Adisa, E AlAmeer, S Alshryda, ... The Lancet 400 (10363), 1607-1617, 2022 | 24 | 2022 |
| Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis S Arelaki, T Koletsa, E Sinakos, V Papadopoulos, K Arvanitakis, ... Virchows Archiv 481 (3), 455-465, 2022 | 19 | 2022 |
| The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications K Arvanitakis, T Koufakis, K Kotsa, G Germanidis Pharmacological Research 181, 106261, 2022 | 19 | 2022 |
| The risk of venous thromboembolic events in patients with inflammatory bowel disease: a systematic review and meta-analysis KD Arvanitakis, AD Arvanitaki, CD Karkos, EΑ Zintzaras, GS Germanidis Annals of gastroenterology 34 (5), 680, 2021 | 18 | 2021 |
| How far beyond diabetes can the benefits of glucagon-like peptide-1 receptor agonists go? A review of the evidence on their effects on hepatocellular carcinoma K Arvanitakis, T Koufakis, K Kotsa, G Germanidis Cancers 14 (19), 4651, 2022 | 17 | 2022 |
| The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks? SP Papadakos, K Arvanitakis, IE Stergiou, V Lekakis, S Davakis, ... Cancers 15 (10), 2795, 2023 | 15 | 2023 |
| Risk for recurrent cardiovascular events and expected risk reduction with optimal treatment 1 year after an acute coronary syndrome S Zafeiropoulos, I Farmakis, A Kartas, A Arvanitaki, A Pagiantza, ... The American Journal of Cardiology 133, 7-14, 2020 | 13 | 2020 |
| The liver cancer immune microenvironment: emerging concepts for myeloid cell profiling with diagnostic and therapeutic implications K Arvanitakis, I Mitroulis, A Chatzigeorgiou, I Elefsiniotis, G Germanidis Cancers 15 (5), 1522, 2023 | 12 | 2023 |
| Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial S Zafeiropoulos, I Farmakis, A Kartas, A Arvanitaki, A Pagiantza, ... Atherosclerosis 323, 37-43, 2021 | 10 | 2021 |
| Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications SP Papadakos, IE Stergiou, N Gkolemi, K Arvanitakis, S Theocharis Cancers 15 (13), 3434, 2023 | 7 | 2023 |
| Adverse pregnancy outcomes in women with celiac disease: a systematic review and meta-analysis K Arvanitakis, A Siargkas, G Germanidis, T Dagklis, I Tsakiridis Annals of Gastroenterology 36 (1), 12, 2023 | 7 | 2023 |
| Meeting at the crossroad between obesity and hepatic carcinogenesis: unique pathophysiological pathways raise expectations for innovative therapeutic approaches K Arvanitakis, SP Papadakos, V Lekakis, T Koufakis, IG Lempesis, ... International Journal of Molecular Sciences 24 (19), 14704, 2023 | 4 | 2023 |
| Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation SP Papadakos, N Machairas, IE Stergiou, K Arvanitakis, G Germanidis, ... Cells 12 (16), 2036, 2023 | 4 | 2023 |
| Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics SP Papadakos, K Arvanitakis, IE Stergiou, C Vallilas, S Sougioultzis, ... Pharmaceutics 15 (10), 2460, 2023 | 3 | 2023 |
| GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and … K Arvanitakis, T Koufakis, D Popovic, G Maltese, O Mustafa, M Doumas, ... Current obesity reports 12 (2), 61-74, 2023 | 3 | 2023 |
| γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy SP Papadakos, K Arvanitakis, IE Stergiou, ML Koutsompina, ... International Journal of Molecular Sciences 25 (3), 1381, 2024 | 1 | 2024 |
| Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential K Arvanitakis, T Koufakis, G Kalopitas, SP Papadakos, K Kotsa, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 102935, 2023 | 1 | 2023 |
| Risk for recurrent cardiovascular events and expected risk reduction with optimal treatment one year after an acute coronary syndrome S Zafeiropoulos, IT Farmakis, A Kartas, A Arvanitaki, A Pagiantza, ... European Heart Journal 41 (Supplement_2), ehaa946. 2969, 2020 | 1 | 2020 |
Georgios GermanidisΕΜΒΙΕΕ (SUBRE)Verified email at auth.gr
